The company has collaborations with organizations from the pharmaceutical, biotech and academic sectors, helping to accelerate drug discovery from target validation and hit identification to candidate nomination.

IRBM has discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing. The company was founded in 2010, as a spin-off from MSD.